Emergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.
© EMERGEX VACCINES
Website by Instinctif Partners
Emergex Vaccines Holding Limited (9955881)
4/5 Dunmore Court,
Abingdon, United Kingdom